| Literature DB >> 34276819 |
Raha Ahmad Raus1, Wan Mohd Fazli Wan Nawawi1,2, Ricca Rahman Nasaruddin1,2.
Abstract
Alginate is an edible heteropolysaccharide that abundantly available in the brown seaweed and the capsule of bacteria such as Azotobacter sp. and Pseudomonas sp. Owing to alginate gel forming capability, it is widely used in food, textile and paper industries; and to a lesser extent in biomedical applications as biomaterial to promote wound healing and tissue regeneration. This is evident from the rising use of alginate-based dressing for heavily exuding wound and their mass availability in the market nowadays. However, alginate also has limitation. When in contact with physiological environment, alginate could gelate into softer structure, consequently limits its potential in the soft tissue regeneration and becomes inappropriate for the usage related to load bearing body parts. To cater this problem, wide range of materials have been added to alginate structure, producing sturdy composite materials. For instance, the incorporation of adhesive peptide and natural polymer or synthetic polymer to alginate moieties creates an improved composite material, which not only possesses better mechanical properties compared to native alginate, but also grants additional healing capability and promote better tissue regeneration. In addition, drug release kinetic and cell viability can be further improved when alginate composite is used as encapsulating agent. In this review, preparation of alginate and alginate composite in various forms (fibre, bead, hydrogel, and 3D-printed matrices) used for biomedical application is described first, followed by the discussion of latest trend related to alginate composite utilization in wound dressing, drug delivery, and tissue engineering applications.Entities:
Keywords: Alginate; Alginate composite; Drug delivery; Tissue engineering; Wound dressing
Year: 2020 PMID: 34276819 PMCID: PMC8261255 DOI: 10.1016/j.ajps.2020.10.001
Source DB: PubMed Journal: Asian J Pharm Sci ISSN: 1818-0876 Impact factor: 6.598
Fig. 1Chemical structure of alginate composed of 1,4-linked β-d-mannuronic acid M and 1,4 α-l-guluronic acid G residues. Adapted with permission from [24]. Copyright (2011), Elsevier.
Alginate composite fibre prepared via wet spinning technique.
| Additive material | Additive material content (%,wt) | Composite preparation | Composite characterisation | Ref. |
|---|---|---|---|---|
| Graphene oxide | 2–8 | Sodium alginate/graphene oxide solution extruded via syringe into CaCl2 bath followed by fibre stretching in CaCl2 bath at 50% and 100% draw ratio | Highest modulus of 9.39 GPa (▲118%) and highest strength of 0.86 GPa (▲169%) obtained at 4% graphene oxide content | |
| Carboxyl methyl chitosan | 10–70 | 4% sodium alginate/5% carboxylmethyl chitosan blend at 9/1, 7/3, 5/5, 3/7 ratio | Highest tenacity of 13.8 cn/tex (▲35%) obtained at 30% filler content | |
| Gelatin | 9–33 | 4% sodium alginate/4% gelatin blend at 10/5, 10/4, 10/3, 10/2, 10/1 ratio | Highest tenacity of 1.29 cn/dtex and highest elongation of 4.41% obtained at 16.7% gelatin content | |
| Cellulose nanocrystal | 0.5–16 | Sodium alginate/cellulose nanocrystal solution extruded via spinneret into 5% CaCl2 bath followed by fibre stretching at 1.2 draw ratio | Highest tenacity of 2.05 cN/dtex (▲33%) and highest elongation of 15% (▲82%) obtained at 2% cellulose nanocrystal content | |
| Chitosan | 1–2 (w/v chitosan solution) | 10% sodium alginate solution extruded via spinneret (1 hole, 0.6 mm diameter) into 8% CaCl2 bath | Highest modulus of 0.43 cN/dtex (▲13%), highest strength of 1.77 cN/dtex (▲13%) and highest elongation of 10% (▲4%) obtained when alginate fibre immersed in 1% chitosan bath | |
| Methylene blue nanocapsule | 3–15 | Nanocapsule first created by blending methylene blue and NaHCO3 with alginate solution | Highest tenacity of 15 cN/dtex (▲16%) obtained at 6% nanocapsule content | |
| Chitin | 33–75 | Alginic acid/chitin dissolved in 1-ethyl-3-methylimidazolium acetate ionic liquid and extruded via syringe into CaCO3 bath. | Composite fibre exhibited 22% decrease in modulus (6.9 GPa), 16% decrease in strength (216 MPa), 9% decrease in elongation (4.1%), and 19% decrease in water uptake (2.06 g/g), but still strong enough to be used directly as structural material for wound care | |
| Silver nanoparticle | 0.05 or 0.005 mM silver nitrate solution | 2% sodium alginate solution extruded via syringe into 1 M CaCl2 bath. | Composite fibre promote faster wound closure, increased epidermal thickness, and decreased neutrophil at local wound site | |
| Starch, salicylic acid drug | 10–70 | Sodium alginate/starch solution extruded via spinneret (30 holes, 0.08 mm diameter) into 10% CaCl2 bath followed by fibre stretching in water at 20% draw ratio | Highest tenacity of 14.2 cN/tex (▲29%) obtained at 10% starch content. | |
| Carrageenanchondrocyte cells | 20–50 | Two type of alginate used in blend: | Noncytotoxic. Higher viability of cells after 3 weeks in | |
| Chitosan whisker | 0.2–1.0 | Sodium alginate/chitosan whisker solution extruded via spinneret (30 holes, 0.02 mm diameter) into 1st coagulation bath (5% CaCl2 in 50% MeOH) and 2nd coagulation bath (MeOH) followed by fibre stretching at 1.2 draw ratio | Highest tenacity of 10 cN/tex (▲67%) obtained at 1% whisker content. | |
| Chitin whisker | 0.05–2 | Sodium alginate/chitin whisker solution extruded via spinneret (30 holes, 0.02 mm diameter) into 1st coagulation bath (5% CaCl2 in 50% MeOH) and 2nd coagulation bath (MeOH) followed by fibre stretching at 1.2 draw ratio | Highest tenacity of 10.4 cN/tex (▲16%) obtained at 0.15% whisker content. | |
| Single walled carbon nanotube (SWCNT) | 0.6–23 | Sodium alginate/SWCNT solution extruded via syringe (0.85 mm diameter) into 1st coagulation (15% CaCl2, 15 min) and 2nd coagulation bath (3% CaCl2, overnight) | Highest modulus of 6.67 GPa (▲93%) and highest strength of 250 MPa (▲25%) obtained at 1.2% SWCNT content | |
| Polypyrrole | 72 | SWCNT is added for the final ratio of pyrrole monomer/sodium alginate/SWCNT at 2.63/1/0.04 | Addition of polypyrrole decrease composite strength by 61% (140 MPa) and elongation by 33% (8%), which may be attributed to the low compatibility of alginate and polypyrrole |
Alginate fibre composite prepared via electrospinning technique.
| Additive material | Additive material content (wt%) | Composite preparation | Composite characterisation | Ref. |
|---|---|---|---|---|
| Essential oil | 0.5–1.5 | Carrier: PVA | Uniform fibres obtained in viscosity range 1120 – 1280 cP. | |
| ZnO NPs | 0.5–5 | Carrier: PVA | Average fibre diameter of 220 – 360 nm. | |
| Chitosan | 70:30 filler/ | Carrier: PEO | Average fibre diameter of 154 nm. | |
| Organic rectorite | 1 | Carrier: PVA | Organic rectorite promote bacterial inhibition ability against | |
| Soy protein isolate (SPI), vancomycin drug | 10–50 | Carrier:PEO | Uniform fibre with average diameter of 200 nm obtained at 5.6/2.4 sodium alginate/PEO blend with 20% filler and further loaded with vancomycin drug | |
| Glutamine | 35 mg/ml | Carrier: polyethylene oxide (PEO) | Average fibre diameter of 160 nm. | |
| Gatifloxacin | 1 | Carrier: PVA | Uniform fibre obtained at 3/7 NaAlg/PEO blend with 1% filler | |
| Pullulan | 10 | Carrier: not used | Continuous and bead free fibre with diameter 57 – 87 nm obtained at sodium alginate concentration between 0.8% to 1.6% | |
| Ciproflaxin | 0.02–0.48 | Carrier: PEO | Uniform fibre with diameter 119 – 161 nm obtained only when surfactant is added | |
| Nano hydroxyl apatite (nHAP) | 1.67–10.02 mg/ml | Carrier: PVA | Addition of 1.64 wt% nHAP enhanced fibre tensile strength enhanced about 45% | |
| Poly-caprolactone (PCL) | 10 | Carrier: not used | Compared to pure PCL scaffold, scaffold that embed alginate/PCL fibre showed significantly enhanced hydrophilic behaviour, water absorption (∼8 fold) and significantly biological activities (∼1.6 fold for cell viability at 7 d ∼2.3 fold for osteogenic differentiation activity at 14 d, and 6.4 fold for calcium mineralisation at 14 d) | |
| Methycrylated gelatin (GelMA) | 20–50 | Carrier: PEO | ||
| Chitosan, silver NP | 1% silver NP in chitosan solution | Carrier: PEO | Silver nanoparticles impregnated into electrospun alginate nanofibres by complexion with chitosan | |
| MgO NP | 10 | Carrier: PVA | Bead free fibre with diameter between 60 – 250 nm |
Fig. 2Schematic of microfluidic concept for (A) continuous alginate microfiber generation. Adapted with permission from [67], Copyright (2007) American Chemical Society, and (B) continuous alginate hollow microfiber generation. Adapted with permission from [68]. Copyright (2009), John Wiley and Sons.
Alginate composite fibre prepared via microfluidic technique.
| Filler | Cell incorporation | Composite preparation | Composite characterisation | Ref. |
|---|---|---|---|---|
| ECM, Methacrylated gelatin (GelMA) | Liver HepG2, embryo fibroblast cells (NIH 3T3), Human umbilical vein endothelial cells (HUVECs) | Microfluidic system: multibarrel capillary inlet and several single-barrel capillaries inlet | Addition of ECM filler reconstruct a microenvironment for cell growth. | |
| GelMA | HUVECs, Human osteoblast-like cells (MG63) | Microfluidic system: double coaxial laminar flow microfluidic system with 3 capillary inlet. The system outlet is immersed in CaCl2 solution. | Addition of filler aimed to offer additional assembly network, strengthen mechanical and biological activity | |
| Collagen | Pancreatic islets from sprague-dawley rat | Microfluidic system: polydimethylsiloxane (pdms) mould with integrated cylindrical and coaxial flow channels fabricated using soft lithography | Collagen added to mimic the native islet microenvironment. | |
| Gelatin or urinary bladder material (ubm) | Osteosarcoma cell (saos-2) | Microfluidic system: micromachined acetal resin serve as template during ‘hydrogel shrinking’ fabrication of microfluidic chip | Gelatin or ubm promote extracellular matrix environment and positively influencing the viability and osteogenic mineralization. | |
| No filler | Mesenchymal stem cells (MSCs) | Microfluidic system: Main inlet channel comprised of 150 – 550 µm diameter glass channel inserted into 1.5 mm rectangular glass tube. Side channel of 1 mm diameter connected to the periphery of rectangular glass tube | Composite fibre shows retention strength value of 0.54 N, which is within the range of the strength needed for tissue engineered tubular graft (0.5 – 0.7 N) | |
| Methacrylated hyaluronic acid (MA-HA) or Methacrylated chondroitin sulfate (MA-CS) with chitosan as complexion agent | Human tendon derived cells (hTDCs) | Microfluidic system: Polydimethysiloxane chip designed with two inlet channel (1 mm diameter) joined to form one common outlet channel (1 mm diameter) | Composite fibre did not affect cell viability and cells were also able to maintain their function of producing extracellular matrix up to 21 d in culture | |
| Chitosan | Liver HepG2 | Microfluidic system: Polydimethysiloxane chip with a tubular core (connected to 1st inlet channel) surrounded with 3 layer of sheath (inner-sheath layer connected to 2nd inlet channel, mid-sheath layer connected to 3rd inlet channel, and outer-sheath layer connected to 4th inlet channel) | The hollow region of fibre composite with chitosan inner coating is able to resist disintegration upon immersion in saline solution. |
Fig. 3Different type of bioprinting technique. (A) laser-based bioprinter use laser focused on an absorbing substrate to generate pressures that forward transfer cell-containing materials onto a collector substrate. (B) droplet-based bioprinting use either thermal or acoustic mechanism to dispense bioink droplet akin to typical inkjet printer. (C) extrusion-based bioprinting utilize pneumatic of mechanical (piston or screw) to dispense continuous bioink filament. Adapted with permission from [88]. Copyright (2013), John Wiley and Sons.
Recent studies on the alginate composites for wound dressing application.
| Additional components to alginate composite | Functions | Performances | Ref. |
|---|---|---|---|
| Chitosan | Bactericidal activity | Better bactericidal activity against Gram (-) bacteria ( | |
| hemolytic properties | Slightly hemolytic. | ||
| Blood clotting | Activate blood-clotting faster than the | ||
| Nano-silica or hydroxyapatite (nHAP) | Tuning the physicochemical properties of alginate reinforced fibres | Addition of nano-silica or HAP delayed degradation and swelling behaviour and increase mechanical performances of the dressing and bioactivity of the wound healing process with no toxicity effects. | |
| Poly(γ-glutamic acid) | Tuning the physicochemical properties of alginate hydrogel | Addition of poly(γ-glutamic acid) improved the swelling property, hemostats and removal of exudates due to the high hydrophilicity of poly(γ-glutamic acid). | |
| Gelatin | Tuning the physicochemical properties of alginate hydrogel | Prolonged sustained the drug release. | |
| Vancomycin | Antimicrobial drug | Antimicrobial activity towards gram positive bacteria. | |
| Halloysite nanotubes | Encapsulate the vancomycin | Extended the release of vancomycin (44% released amount) as compared to silica microcapsule (70% released amount). | |
| Natural polyols ( | Tuning the physicochemical properties of alginate foam dressing sheets | Nontoxic foam with higher density, lower porosity, better water absorption, higher strength and faster foam degradation than alginate foam without natural polyols. | |
| Silver nanoparticles (Ag NPs) and asiaticoside (AS) | Antimicrobial agents | Combination of Ag NPs and AS showed better antibacterial activity toward | |
| Tuning the physicochemical properties of alginate hydrogel film | Addition of ACE improved the tensile strength, swelling rate and thermal stability of alginate film. | ||
| Oxygen-releasing microspheres (ORM) containing hydrogen peroxide (H2O2) incorporated into poly(lactic-co-glycolic acid) | Forming a sustained release of oxygen to cells and tissues | Caused effective tissue regeneration wound healing by inducing neovascularization and promoting cell proliferation. | |
| Manuka honey | Tuning the physicochemical properties of alginate hydrogel film | Addition of Manuka honey decreased the swelling rate and gel fraction but increased the Young Modulus and tensile strength. | |
| Promote cell proliferation | Addition of RCSPs promoted collagen deposition, enhanced epidermal regeneration and faster hemostasis thus effectively promote wound healing. | ||
| Collagen @ polyacrylamide (PAM-Col) | Mix with oxidized sodium alginate as a new cross linker (COA) to form composite hydrogel | PAM-Col-COA composite hydrogel showed good mechanical properties, skin tissue adhesion, water absorption and sustained biological activity. | |
| Chitosan | Forming stable shell (microcapsule) for drug delivery (Chinese nutgall) | Biocompatible and long-term durability for maintaining a long-term drug release. Ease of storage (−20 °C for more than 60 h). Also contribute to the antimicrobial activity | |
| Chinese nutgall | Antimicrobial drug | Inhibition rate of 98.99% against | |
| Activated charcoal | As adsorbent | Adsorbed toxins, malodour molecules and tissue degradation products | |
| Zinc ions (Zn2+) | Antimicrobial agent | Inhibit the |
Fig. 4Design and principle of SA/HS composite hydrogel for wound healing. (A) Diagrammatic sketch of wound healing with hydrogel; (B) HS particles release ions into solution; (C) structure of SA/HS composite hydrogel. (D) Wound closure at Days 3, 7, 14, and 21 after treatment with the composite hydrogel dressing. Adapted with permission from [102]. Copyright (2017), American Chemical Society.
Fig. 5(A) Preparation routine of single-membrane and double-membrane microsphere hydrogels; optical microscope images of (B) the SA/CCNC single-membrane microsphere hydrogel, (C) the SA/CCNC-1 h double-membrane microsphere hydrogel. Complexing drug release study involving ceftazidime hydrate (CH, the open symbols) and epidermal growth factor human (EGF, the solid symbols) of the double-membrane hydrogels in the pH 7.4 buffer solution (D) drug release profiles, (E) UV spectra of CH release for the SA/CCNC-1 h double-membrane hydrogel at the critical times, and (F) UV spectra of EGF release for the SA/CCNC-1 h double membrane hydrogel with the Bradford method at the critical times. Adapted with permission from [144]. Copyright (2016), American Chemical Society.
Utilization of alginate for tissue engineering of various tissues/organs.
| Organ/cells | Function | Ref. |
|---|---|---|
| MC3T3-E1 osteoblast cells | Increase MC3T3-E1 osteoblast cells survivability in alginate beads | |
| Femur in rabbits | Repair osteochondral defect in patella groove of the distal femur in rabbits (4.5 mm in diameter and 3 mm in depth) using ultrapurified alginate gel carrying stromal cell-derived factor-1 | |
| Chondrocytes | Promotes both chondrocyte proliferation and maintenance of the chondrogenic phenotype in three dimensional alginate sulfate hydrogels | |
| Liver | Proliferation of encapsulated HepG2/C3A liver cells for | |
| Liver | Generation of multilayered 3D structures of HepG2 liver cells using a bio-printed 3D alginate | |
| Cornea | Propagating corneal epithelial cells for limbal epithelial therapeutic | |
| Vascular | Propagation of human fat-derived stromal vascular fraction cells in 3D alginate spheroids. The 3D alginate spheroid was formed by direct-write three-dimensional printing system in which 1.5% (w/v) alginate solutions was mixed with human fat-derived stromal vascular fraction cells | |
| Heart | Improved left ventricular function of rats suffered from myocardial infarct after injection of alginate hydrogel with a unique microstructure of uniform capillary-like channels | |
| Testis | Improved seminiferous tubule integrity and spermatogonial recovery when grafted with alginate encapsulated immature testicular tissue | |
| Vascular of adipose tissue | Promotes revascularization of mice adipose tissue when implanted with VEGF-calcium alginate microspheres loaded with adipocytes |
Fig. 6Surface morphology of 50/50 alginate/HAP composite scaffolds (3% alginate, crosslinker: 0.03 M CaCl2, freezing temperature: −40 °C) at (A) bottom, (B) top, and (C) midsections of scaffolds. Magnification at 100 × . Adapted with permission from [180]. Copyright (2004), John Wiley and Sons.
Fig. 7Phase contrast image of poly(ethylene glycol)-microencapsulated mesenchymal stem cells for bone tissue engineering. Adapted with permission from [215]. Copyright (2012), Authors.
Fig. 8Typical eyeball images after operation. (A-D) Negative control group on the 15th, 30th, 45th and 60th day; (E-F) experimental group receiving encapsulated corneal endothelial cells (CECs) in hydroxypropyl chitosan/oxidized alginate on 15th, 30th, 45th and 60th day. Adapted with permission from [229]. Copyright (2011), Elsevier.